All News

RheumNow Podcast square

EULAR 2023 Notes from Milan (6.09.2023)

Jack Cush, MD

Dr. Jack Cush reviews highlight abstracts and sessions - covering lupus, RA, gout, Still's disease, safety data, AI in medicine and more - from last week's EULAR 2023 Congress held in Milan, Italy.

Read Article
EULAR19.abstract.jpg (keep)

EULAR 2023 – Day 4 Report

Jack Cush, MD

Day 4 was a half day closeout to the EULAR 2023 Congress.

Read Article
exhibitor.floor.ACR

EULAR 2023 – Day 3 Report

Jack Cush, MD

Day 3 was a sunny warm day in Milan at the 2023 EULAR Congress meeting. Here are a few of my favorite abstracts from today.

Read Article
pregnant, pregnancy, mother, fertility

Unmasking Lupus Pregnancy: Adherence and Drug Monitoring Dilemmas

Bella Mehta, MBBS, MS

Risk of poor pregnancy outcomes in lupus patients continues to remain high, especially in the setting of high disease activity. Preliminary data from a lupus pregnancy LEGACY cohort presented at EULAR 2023 raise concern.

Read Article
hip.THR_.jpg

EULAR 2023 – Day 1 Report

Jack Cush, MD

EULAR 2023 launched today to crowds of attendees.  The opening Plenary session and presidential address by Dr.

Read Article
arthritis.RA_.Xray_.hands_.jpg (keep)

An update on JAK inhibitors and cardiovascular risks

Antoni Chan, MD, PhD

In the last 2 years, there has been more caution and vigilance with the use of JAK inhibitors in the treatment of rheumatoid arthritis due to the risk of CV events, including MACE and VTE. The ORAL surveillance study, a post-approval safety study conducted in RA patients aged ≥50 years with ≥1 CV risk factor, has resulted in increased caution and greater emphasis on assessment of MACE and VTE risks in patients starting JAK inhibitors. 

Read Article
Convention1.jpg

EULAR 2023: Featured Industry Presentations

Jack Cush, MD

EULAR 2023 opens tomorrow, Wednesday May 31st, with hundreds of novel presentations and pivotal clinical trials, many being featured industry sponsored clinical trials and research on their novel agents. Below is a collection of the featured abstracts, and presentation times from EULAR

Read Article
cush.tkr_.jpg

Colchicine and the Risk of Knee and Hip Replacement

Jack Cush, MD

Treatment of osteoarthritis is a major unmet need, as there are few therapies effective at pain control and no options for disease modification; yet a new trial in Annals of Internal Medicine suggest that chronic low dose colchicine may alter disease progression and lower the risk of of total knee and total hip replacements.

Read Article
What happens when an AI-based symptom checker & an online self-referral tool play Rheumatologists? They don't seem to do great yet! 600 new pts, outw/ 36% dvlpd IA IA Sens 62% Spe 47% Tool Sens 66% Spe 54% More work needed to implement these in practice #EULAR23 @Rheumnow

Aurelie Najm AurelieRheumo ( View Tweet)

I hurt because the weather is COLD! Data from Rhumadata in 14000 pt encounters show higher pt GLOBAL in winter vs summer - NB cold in Quebec #EULAR2023 POS0324 @RheumNow Small differences but maybe a script to go south is the right Rx! https://t.co/tjd6FjEHij
Janet Pope Janetbirdope ( View Tweet)
✅Benefit of adding #HydroxyChloroquine #HCQ in refractory obstetric #APS #EULAR2023 poster https://t.co/dgGY496dbh
Dr Gurdeep Dulay gurdeep_dulay ( View Tweet)
#EULAR2023 #OP0289 We need to improve health equity in the care of people with arthritis. An online survey showed that Black, Indigenous and People of Colour (BIPOC) Women in Canada faced a)unique & disproportionate barriers and b) complex experiences of discrimination @RheumNow https://t.co/hnahUIb9Xb
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Can machine learning help bDMARD selection in RA? Early days limited by the data available, so not great yet, but efforts underway are a good start for an area where we need to do better than our status quo guessing. Watch this space POS0641 #EULAR2023 @RheumNow https://t.co/2j8H40iFWo
David Liew drdavidliew ( View Tweet)
TNFi & Disease activity-guided dose optimization in RA⬇️prog of ADA or ETA daily dose (100%66%50%0%) 10yrs followup in 170pts ⭐️74% tapered until full discontinuation ⭐️Median time to restart 8 mo ⭐️21% never restarted! What's lacking? % of recovery @Rheumnow OP0131 #EULAR23 https://t.co/Ms6lqQ7cWf
Aurelie Najm AurelieRheumo ( View Tweet)
#EULAR2023 OP0083-HPR Stretch & Strength training is key! An RCT in Brazil shows: Pilates x 3/week is more effective in reducing pain, HRQoL, psychological effects & analgaesic consumption VS Aerobic walking on treadmill x 3/week for 12 weeks in women with Fibromyalgia @RheumNow https://t.co/CzIH9Xd8Ku
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
I swear it is muscle, Doctor! GLORIA trial substudy Pred 5 mg/day 2 years in RA pts >65yo: Weight gain 1kg vs. PBO, no increase or redistribution of fat mass but augmentation in lean mass 💪 Probably explained by better disease control (although NS in study, small sample size)

Aurelie Najm AurelieRheumo ( View Tweet)

#EULAR2023 Abstr #OP0048 What happened if we taper steroid in #lupus patients who are Serologically Active Clinically Quiescent? A cohort study in Asia showed: - Tapering was NOT associated with subsequent flare - Tapering reduced damage in those on =>5mg/day @RheumNow https://t.co/Q6GiaSCgV6
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Leiden arthritis clinic: 1000+ pts w/ RA & high BMI associated w/ < MRI-detected osteitis at dis onset but NOT synovitis RA w/ overweight/obesity 25% < MRI-detected erosive progression at 2 yrs More marked in ACPA+ pts Is leptin the missing link? 🤓 OP0039 #EULAR23 @Rheumnow https://t.co/RRSV9VlRtn
Aurelie Najm AurelieRheumo ( View Tweet)
Biosimilar vs originator: as switches loom in the US, once again it’s really hard to say we see any differences in drug survival for our RA patients These data from forced switching in BC, Canada are just like the others - biosimilars are business as usual. POS0567 #EULAR2023 https://t.co/Ebl1hTM4qE
David Liew drdavidliew ( View Tweet)
There are lots of reasons why axSpA treatments fail for patients. And as rheumatologists, we can’t just prescribe and walk away - we need to address each in turn, for our patients’ sake #EULAR2023 @RheumNow https://t.co/hzo57BaEXw
David Liew drdavidliew ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×